Form 4: Travere Therapeutics CCO Reports Equity Transactions

Travere Therapeutics' Chief Commercial Officer, Peter Heerma, reported the acquisition of restricted stock units and stock options, alongside a 'sell to cover' transaction for tax obligations.

Summary

• Peter Heerma, Chief Commercial Officer of Travere Therapeutics, Inc. (TVTX), reported recent equity transactions.
• On January 31, 2026, Heerma acquired 26,120 shares of Common Stock through restricted stock units (RSUs) at a price of $0.
• Also on January 31, 2026, Heerma was granted 69,640 employee stock options with an exercise price of $33.095.
• On February 3, 2026, Heerma disposed of 7,310 shares of Common Stock at $32.12 per share.
• This disposition was a mandatory "sell to cover" transaction to satisfy tax withholding obligations related to the settlement of vested restricted stock units, not a discretionary trade.
• Following these transactions, Heerma beneficially owns 131,823 shares of Common Stock directly and 69,640 employee stock options directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects ongoing executive equity compensation, aligning management interests with shareholders, despite a non-discretionary tax-related sale.

Positives

• Grant of 26,120 restricted stock units (RSUs) to the Chief Commercial Officer, indicating continued equity incentive.
• Grant of 69,640 employee stock options, aligning management's interests with shareholder value.

Negatives

• Disposition of 7,310 shares of Common Stock, although this was a non-discretionary "sell to cover" for tax purposes.

Future Outlook

na

Industry Context

StockSavvy.ai notes that insider equity grants and "sell to cover" transactions are routine events in executive compensation, reflecting standard practices for aligning executive incentives with company performance and managing tax liabilities on vested equity. This filing does not provide broader industry context.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a Chief Commercial Officer is a standard practice in the biotechnology and pharmaceutical industry for executive compensation, aiming to incentivize long-term performance and retention.
• The "sell to cover" transaction for tax withholding is a common mechanism across all industries for executives to meet tax obligations upon the vesting or exercise of equity awards, rather than a discretionary sale.

Stakeholder Impact

• Shareholders: The grants of RSUs and stock options align the Chief Commercial Officer's financial interests with long-term shareholder value creation. The "sell to cover" transaction is a routine event and does not reflect a change in management's confidence.
• Employees: Reflects the company's ongoing use of equity compensation as part of its incentive structure for key executives.

Next Steps

• One-fourth of the granted stock options will vest and become exercisable on January 31, 2027.
• The remaining stock options will vest in 36 equal monthly installments thereafter.

Key Dates

Recommendation

The filing details routine insider equity compensation and a non-discretionary tax-related sale. These transactions are standard and do not provide new fundamental information to warrant a change in investment recommendation. Investors should hold based on existing company fundamentals.

Keywords

Travere Therapeutics, TVTX, Peter Heerma, Chief Commercial Officer, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, Sell to Cover